非ホジキンリンパ腫治療市場：治療タイプ、用途、エンドユーザー別-2025-2030年の世界予測

非ホジキンリンパ腫治療市場は、2023年に82億米ドルと評価され、2024年には88億4,000万米ドルに達すると予測され、CAGR 7.91％で成長し、2030年には139億8,000万米ドルに達すると予測されています。

非ホジキンリンパ腫（NHL）治療市場の範囲は、化学療法、免疫療法、標的療法、放射線療法などの薬理学的介入を中心に、様々なサブタイプのNHLの診断、治療、管理を包含します。ヘルスケアプロバイダー、製薬会社、研究者、効果的で革新的な治療法を求める患者に関連します。非ホジキンリンパ腫治療の必要性は、その有病率と長期的で効果的な治療オプションに対するアンメットニーズによって強調されています。この市場には、病院、がん研究機関、専門クリニックなど多様な用途があり、精密医療の進歩と医療費の増加によって需要が拡大しています。最終用途の範囲は、初回診断から再発または寛解のモニタリングまで、NHLの人口統計や病期を問わず患者を対象としています。市場の洞察では、非ホジキンリンパ腫の罹患率の増加、バイオテクノロジーの進歩、新規治療オプションの承認が成長に影響していることが明らかになっています。高い治療費、治療に関連した副作用、NHLのサブタイプの複雑さなどの課題は、一貫した患者の転帰のためのハードルを作り出しています。CAR T細胞療法や二重特異性抗体の出現は、有効性の向上と個別化治療の大きな可能性を示しています。推奨される治療法としては、革新的治療のための研究開発への投資、臨床試験強化のためのパートナーシップの活用、費用対効果の高い治療レジメンの開発に注力することなどが挙げられます。制約事項としては、市場参入に影響を及ぼす可能性のある厳しい規制環境と償還の問題があります。技術革新と研究の最良の領域は、免疫療法の有効性の向上、予後と治療戦略のための人工知能の統合、患者の転帰を改善するために異なる治療法を組み合わせる併用療法の探求にあります。非ホジキンリンパ腫の治療市場は競争的でダイナミックであり、科学的進歩に重点が置かれているため、非ホジキンリンパ腫患者のQOLと生存率を向上させるビジネスに大きな可能性があります。

市場力学：急速に進化する非ホジキンリンパ腫治療市場の主要市場インサイトを公開

非ホジキンリンパ腫治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 非ホジキンリンパ腫の有病率の上昇
  • リンパ腫に対する有望な薬剤の上市と薬剤承認
  • 非ホジキンリンパ腫患者の予後と標準治療の重視
• 市場抑制要因
  • 治療費の高騰と特定の副作用
• 市場機会
  • 非ホジキンリンパ腫に対する治療薬の研究開発の増加
  • 政府および非営利団体からの投資の増加
• 市場の課題
  • がん治療の選択肢に対する厳しい規制

ポーターのファイブフォース：非ホジキンリンパ腫治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：非ホジキンリンパ腫治療市場における外部からの影響の把握

外部マクロ環境要因は、非ホジキンリンパ腫治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析非ホジキンリンパ腫治療市場における競合情勢の把握

非ホジキンリンパ腫治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス非ホジキンリンパ腫治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、非ホジキンリンパ腫治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨非ホジキンリンパ腫治療市場における成功への道筋を描く

非ホジキンリンパ腫治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 非ホジキンリンパ腫の罹患率の上昇
    • リンパ腫に対する有望な薬の発売と薬の承認
    • NHL患者の予後と第一線の治療計画における標準治療に重点を置く
  • 抑制要因
    • 治療費が高く、副作用もある
  • 機会
    • 病気に対する治療薬の研究開発の増加
    • 政府や非営利団体からの投資増加
  • 課題
    • がん治療の選択肢に対する厳しい規制
• 市場セグメンテーション分析
  • 治療の種類：がんが体の他の部位に広がるのを防ぐための化学療法
  • 応用：びまん性大細胞型B細胞リンパ腫（DLBCL）の進行期治療における免疫療法と放射線の利用
  • エンドユーザー：病院におけるNHL治療のための新しい戦略の採用の増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 非ホジキンリンパ腫治療市場治療の種類別

• 化学療法
• 免疫療法
• 放射線治療
• 幹細胞移植
• 標的療法

第7章 非ホジキンリンパ腫治療市場：用途別

• びまん性大細胞型B細胞リンパ腫
• 濾胞性リンパ腫
• マントル細胞リンパ腫

第8章 非ホジキンリンパ腫治療市場：エンドユーザー別

• がんセンター
• ホームケア
• 病院

第9章 南北アメリカの非ホジキンリンパ腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の非ホジキンリンパ腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの非ホジキンリンパ腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • EPKINLY（エプコリタマブ-bysp）が、再発性または難治性のびまん性大細胞型B細胞リンパ腫（DLBCL）の成人患者を治療する初のかつ唯一の二重特異性抗体として米国FDAに承認されました。
  • ヤンセン、次世代CAR-T療法の開発に向け、セルラー・バイオメディシン・グループと世界規模の提携およびライセンス契約を締結
  • バイオジェン、抗CD20コラボレーションの一環として後期段階の二重特異性抗体の商業化の可能性に対するロイヤルティを受け取ることでジェネンテックと合意
• 戦略分析と提言

企業一覧

• AstraZeneca PLC
• Aurobindo Pharma
• Bayer AG
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Hetero Drugs Ltd.
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Janssen Global Services, LLC
• Kyowa Kirin Co., Ltd.
• Lupin Ltd.
• Merck KGaA
• Nordic Nanovector ASA by Thor Medical
• Novartis AG
• Pharmacyclics, LLC
• Salvavidas Pharmaceutical Pvt. Ltd.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Pharmaceuticals

LIST OF FIGURES

• FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Non-Hodgkin Lymphoma Treatment Market was valued at USD 8.20 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.91%, to USD 13.98 billion by 2030.

The scope of the Non-Hodgkin Lymphoma (NHL) treatment market encompasses the diagnosis, treatment, and management of various subtypes of NHL, focusing on pharmacologic interventions such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy. It pertains to healthcare providers, pharmaceutical companies, researchers, and patients seeking effective, innovative treatments. The necessity for NHL treatment is underscored by its prevalence and the unmet need for long-term, effective treatment options. This market has diverse applications including hospitals, cancer research institutes, and specialty clinics, with growing demand fueled by advances in precision medicine and increased healthcare expenditure. The end-use scope covers patients across demographics and stages of NHL, from initial diagnosis to relapse or remission monitoring. Market insights reveal growth influenced by the increasing incidence of NHL, advances in biotechnology, and the approval of novel treatment options. Challenges such as high treatment costs, adverse treatment-related side effects, and the complexity of NHL subtypes create hurdles for consistent patient outcomes. Opportunities arise with the advent of CAR T-cell therapy and bispecific antibodies, presenting significant potential for improved efficacy and personalized care. Recommendations include investing in R&D for innovative therapies, leveraging partnerships for enhanced clinical trials, and focusing on developing cost-effective treatment regimens. Constraints include stringent regulatory environments and reimbursement issues that may affect market accessibility. The best areas for innovation and research lie in enhancing the efficacy of immunotherapies, integrating artificial intelligence for prognosis and treatment strategies, and exploring combination therapies that combine different treatment modalities to improve patient outcomes. The NHL treatment market is competitive and dynamic, with a robust focus on scientific advancements, offering substantial potential for businesses dedicated to improving the quality of life and survival rates for NHL patients.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Hodgkin Lymphoma Treatment Market

The Non-Hodgkin Lymphoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of non-Hodgkin lymphoma disease
  • The launch of promising drugs and drug approval for lymphomas
  • Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
• Market Restraints
  • High cost of the treatment and certain side effects
• Market Opportunities
  • Increase in research and development of therapeutic drugs against the disease
  • Rising investments from government and non-profit organizations
• Market Challenges
  • Stringent regulations for cancer treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Non-Hodgkin Lymphoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Hodgkin Lymphoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Hodgkin Lymphoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Hodgkin Lymphoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Hodgkin Lymphoma Treatment Market

A detailed market share analysis in the Non-Hodgkin Lymphoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Hodgkin Lymphoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Hodgkin Lymphoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Hodgkin Lymphoma Treatment Market

A strategic analysis of the Non-Hodgkin Lymphoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.
• Based on Application, market is studied across Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
• Based on End-User, market is studied across Cancer Centers, Home Care, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
    • 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
    • 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the treatment and certain side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
    • 5.1.3.2. Rising investments from government and non-profit organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for cancer treatment options
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
  • 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
  • 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Radiation Therapy
• 6.5. Stem Cell Transplantation
• 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

• 7.1. Introduction
• 7.2. Diffuse Large B-cell Lymphoma
• 7.3. Follicular Lymphoma
• 7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Cancer Centers
• 8.3. Home Care
• 8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
  • 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Aurobindo Pharma
• 3. Bayer AG
• 4. Cipla Inc.
• 5. Dr. Reddy's Laboratories Ltd.
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche Ltd.
• 8. Gilead Sciences, Inc.
• 9. GlaxoSmithKline PLC
• 10. Hetero Drugs Ltd.
• 11. Hikma Pharmaceuticals PLC
• 12. Intas Pharmaceuticals Ltd.
• 13. Janssen Global Services, LLC
• 14. Kyowa Kirin Co., Ltd.
• 15. Lupin Ltd.
• 16. Merck KGaA
• 17. Nordic Nanovector ASA by Thor Medical
• 18. Novartis AG
• 19. Pharmacyclics, LLC
• 20. Salvavidas Pharmaceutical Pvt. Ltd.
• 21. Sanofi S.A.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Zydus Pharmaceuticals